Showing results (11-20 of 41) with videos related to
Sort By:
Pageof 5
Langenbeck'S Archives of Surgery|May 8, 2009
Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implicationsIvan Ischenko, Hendrik Seeliger, Axel Kleespies, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabineAxel Kleespies, Ivan Ischenko, Martin E Eichhorn, et al.Journal of Experimental & Clinical Cancer Research : CR|May 1, 2015
Extrinsic intestinal denervation modulates tumor development in the small intestine of Apc(Min/+) miceVerena Liu, Alexandra Dietrich, Michael S Kasparek, et al.BMC Cancer|October 31, 2018
Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinomaHendrik Seeliger, Ioannis Pozios, Gerald Assmann, et al.Plos One|March 6, 2013
Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgeryEike Gallmeier, Dominik C Bader, Lydia Kriegl, et al.Cancers|January 21, 2023
Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic CancerNina A Hering, Emily Günzler, Marco Arndt, et al.Journal of Cancer Research and Clinical Oncology|July 27, 2018
Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinomaIoannis Pozios, Thomas Knösel, Yue Zhao, et al.Biological Chemistry|October 7, 2009
EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cellsPeter Camaj, Hendrik Seeliger, Ivan Ischenko, et al.Cancers|February 15, 2022
Is Laterality Prognostic in Resected KRAS-Mutated Colorectal Liver Metastases? A Systematic Review and Meta-AnalysisMichail Belias, Kazunari Sasaki, Jane Wang, et al.Journal of Cancer Research and Clinical Oncology|December 10, 2022
Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144Ioannis Pozios, Nina A Hering, Emily Guenzler, et al.Pageof 5